Alx Oncology Holdings (ALXO) Liabilities and Shareholders Equity (2019 - 2026)

Alx Oncology Holdings' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $178.3 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 47.5% year-over-year to $178.3 million; the TTM figure through Mar 2026 stood at $415.4 million (down 37.91% YoY), while the FY2025 annual figure was $59.0 million, down 60.04% from the prior year.
• Liabilities and Shareholders Equity came in at $178.3 million for Q1 2026 at Alx Oncology Holdings, up from $59.0 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $363.7 million in Q1 2022 to a low of $59.0 million in Q4 2025.
• A 5-year average of $212.8 million and a median of $214.6 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity slumped 60.04% in 2025 and soared 47.5% in 2026, its largest moves.
• Alx Oncology Holdings' Liabilities and Shareholders Equity stood at $306.5 million in 2022, then decreased by 20.86% to $242.6 million in 2023, then tumbled by 39.08% to $147.8 million in 2024, then plunged by 60.04% to $59.0 million in 2025, then soared by 202.02% to $178.3 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $178.3 million, $59.0 million, and $82.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison